CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:BCMA-targeted CAR-T cell therapies in relapsed and/or refractory multiple myeloma: latest updates from 2023 ASCO Annual Meeting.
BCMA-targeted CAR-T cell therapies in relapsed and/or refractory multiple myeloma: latest updates from 2023 ASCO Annual Meeting.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
利用B细胞成熟抗原(BCMA)这一新型治疗靶点治疗复发和/或难治性多发性骨髓瘤(RRMM)已展现出惊人的结果,促使靶向BCMA的嵌合抗原受体(CAR)-T细胞疗法在RRMM中获得监管批准。目前已有两种获批的靶向BCMA的CAR-T 细胞疗法,全球研究人员正致力于在此基础上进一步改进靶向BCMA的疗法。我们讨论了促成CAR-T 获批的关键研究的长期数据、支持其在更早期治疗线中应用的3期试验,以及旨在缩短静脉到静脉时间的新型生产平台。我们重点介绍了2023年ASCO年会上的五篇关键摘要,这些摘要展示了靶向BCMA的CAR-T 细胞疗法在RRMM中的这些令人振奋的进展。
Treatment of relapsed and/or refractory multiple myeloma (RRMM) utilizing the novel therapeutic target of the B-cell maturation antigen (BCMA) has demonstrated incredible results, leading to regulatory approval of BCMA-targeted chimeric antigen receptor (CAR)-T cell therapies in RRMM. With now two approved BCMA-targeted CAR-T cell therapies, investigators globally are working to build off and improve upon BCMA-targeted therapies.
We discuss long-term data from the pivotal study that led to CAR-T approval, a phase 3 trial supporting their use in earlier lines, and novel manufacturing platforms to decrease vein-to-vein time.
We highlight five key abstracts from the 2023 ASCO Annual Meeting that showcase these exciting updates in BCMA-directed CAR-T cell therapies in RRMM.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。